1214 related articles for article (PubMed ID: 27094798)
21. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
Camidge DR; Kono SA; Lu X; Okuyama S; Barón AE; Oton AB; Davies AM; Varella-Garcia M; Franklin W; Doebele RC
J Thorac Oncol; 2011 Apr; 6(4):774-80. PubMed ID: 21336183
[TBL] [Abstract][Full Text] [Related]
22. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
23. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
Gow CH; Hsieh MS; Wu SG; Shih JY
Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
[TBL] [Abstract][Full Text] [Related]
24. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
25. [Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].
Cao H; Zheng J; Zhao J; Guo XJ; Zhou JY; Ding W; Zhou JY
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):120-125. PubMed ID: 32062881
[No Abstract] [Full Text] [Related]
26. [Gene Expression and Clinical Characteristics of Molecular Targeted Therapy
in Non-small Cell Lung Cancer Patients in Shandong].
Qiao X; Ai D; Liang H; Mu D; Guo Q
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):14-20. PubMed ID: 28103968
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement.
Hayashi H; Okamoto I; Kimura H; Sakai K; Nishimura Y; Nishio K; Nakagawa K
Anticancer Res; 2012 Oct; 32(10):4533-7. PubMed ID: 23060582
[TBL] [Abstract][Full Text] [Related]
28. Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions.
Rosell R; Pedraz-Valdunciel C; Jain A; Shivamallu C; Aguilar A
Expert Opin Investig Drugs; 2024 Mar; 33(3):171-182. PubMed ID: 38372666
[TBL] [Abstract][Full Text] [Related]
29. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
30. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
[TBL] [Abstract][Full Text] [Related]
31. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
[TBL] [Abstract][Full Text] [Related]
32. Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion.
Wu SG; Liu YN; Yu CJ; Yang JC; Shih JY
Genes Chromosomes Cancer; 2018 Oct; 57(10):513-521. PubMed ID: 30107055
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
Drilon A; Bergagnini I; Delasos L; Sabari J; Woo KM; Plodkowski A; Wang L; Hellmann MD; Joubert P; Sima CS; Smith R; Somwar R; Rekhtman N; Ladanyi M; Riely GJ; Kris MG
Ann Oncol; 2016 Jul; 27(7):1286-91. PubMed ID: 27056998
[TBL] [Abstract][Full Text] [Related]
34. Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report.
Dong L; Xia J; Zhang J; Zhang Y; Zhu N; Zhang P; Zhang Y; Zhang X; Li S
BMC Pulm Med; 2018 Jan; 18(1):13. PubMed ID: 29361925
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
Takahashi T; Sonobe M; Kobayashi M; Yoshizawa A; Menju T; Nakayama E; Mino N; Iwakiri S; Sato K; Miyahara R; Okubo K; Manabe T; Date H
Ann Surg Oncol; 2010 Mar; 17(3):889-97. PubMed ID: 20183914
[TBL] [Abstract][Full Text] [Related]
36. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
[TBL] [Abstract][Full Text] [Related]
37. Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4- ALK fusion gene in lung adenocarcinoma patients.
Wang WT; Li Y; Ma J; Chen XB; Qin JJ
Asian Pac J Cancer Prev; 2014; 15(9):3927-32. PubMed ID: 24935562
[TBL] [Abstract][Full Text] [Related]
38. KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas.
Kim JO; Lee J; Shin JY; Oh JE; Jung CK; Park JK; Sung SW; Bae SJ; Min HJ; Kim D; Park JY; Kang JH
Diagn Pathol; 2015 Aug; 10():143. PubMed ID: 26268359
[TBL] [Abstract][Full Text] [Related]
39. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
[TBL] [Abstract][Full Text] [Related]
40. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
